{"filings":[{"id":2061120,"accession_number":"0001665988-26-000041","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-08-05T11:40:11+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bioventus Q2 revenue $153.2M (+4%), GAAP EPS $0.47; initiates strategic alternatives review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $153.2M (+4% YoY); GAAP EPS $0.47 vs $0.11; non-GAAP EPS $0.22 vs $0.21.","Pain Treatments revenue $81.7M (+11.5%); Surgical Solutions $50.4M (-4.5%); Restorative Therapies $21.1M (-2.4%).","Reaffirmed FY2026 guidance: net sales $600-610M, adjusted EPS $0.75-0.79, cash from ops $84-89M.","Board formed independent committee to evaluate strategic alternatives including sale, after unsolicited proposal.","Made $20M discretionary principal prepayment on term loan during Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":285297000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843316,"accession_number":"0001665988-26-000035","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-06-04T11:54:06+00:00","items":["5.07"],"status":"ready","headline":"Bioventus stockholders elect all 12 director nominees and ratify Grant Thornton as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; votes-for ranged from 61.7M (Sutter) to 68.5M (Dhankhar).","Stockholders ratified Grant Thornton LLP as independent auditor for FY 2026 with 75.2M votes in favor.","Approximately 90.23% of outstanding shares (75.3M shares) were represented at the meeting.","Director Martin P. Sutter received 6.8M withheld votes, more than any other nominee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":583876,"accession_number":"0001665988-26-000029","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-05-21T20:58:18+00:00","items":["7.01"],"status":"ready","headline":"Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA reclassified non-invasive bone growth stimulators, including Bioventus' Exogen Ultrasound Bone Healing System, from Class III to Class II on April 16, 2026.","CMS updated Medicare fee schedule for HCPCS codes E0747, E0748, and E0760 for services on or after May 18, 2026.","Bioventus does not expect material impact from reimbursement rate changes on its FY2026 financial results.","Company reiterates previously issued 2026 financial guidance despite the regulatory changes.","Bioventus continues to evaluate long-term impact; future CMS actions could require revised outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94529,"accession_number":"0001665988-26-000026","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 revenue up 7% to $132.1M; GAAP EPS $0.04, raises FY26 EPS and CFO guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $132.1M (+7% YoY); GAAP EPS $0.04 vs -$0.04; Non-GAAP EPS $0.15 vs $0.08 (+88%).","Adjusted EBITDA $23.9M (+24% from $19.2M); cash from ops $8.9M vs -$19.3M.","Pain Treatments +7.7%, Surgical Solutions +6.2%, Restorative Therapies +4.6%; International +17.1%.","Raised FY26 Adj EPS guidance to $0.75-$0.79 (up $0.02), CFO to $84-$89M (up $2M); reaffirms rev $600-610M.","Discretionary $22M term loan prepayment on Mar 27 reduces debt and future interest."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":132089000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106978,"accession_number":"0001665988-26-000010","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q4 GAAP EPS $0.21, revenue $157.9M; guides FY2026 sales $600-610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $157.9M (+2.8% reported, +10.0% organic); GAAP EPS $0.21 (vs $0.00); non-GAAP EPS $0.24; Adj. EBITDA $36.7M (+30%).","Full year 2025 revenue $568.1M (-0.9% reported, +7.5% organic); GAAP EPS $0.33 (vs -$0.56); Adj. EPS $0.68 (+21.4%).","FY2026 guidance: net sales $600-610M (6-7% growth); Adj. EPS $0.73-$0.77 (7-13% growth); cash from ops $82-87M.","Q4 cash from operations $38M (+97% YoY); full year cash from ops up 92%; debt reduced by $29M in Q4.","Launched PNS products StimTrial and TalisMann; added Megan Rosengarten as SVP/GM PNS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123318,"accession_number":"0001665988-25-000032","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bioventus appoints Ajay Dhankhar to board as Smith & Nephew designee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective November 14, 2025; Dhankhar serves as Class II director until 2026 annual meeting.","Dhankhar is Chief Corporate Development & Strategy Officer at Smith & Nephew (SNN) since June 2025.","He is the second designee from S+N stockholders under the Stockholders Agreement.","Dhankhar will not receive any compensation from Bioventus for board service.","No family relationships or material interests in any transaction with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123317,"accession_number":"0001665988-25-000025","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.","Non-GAAP EPS $0.15, up 200% from $0.05; Adjusted EBITDA $26.6M (+12.9%) with margin 19.2%.","Organic revenue growth 8.2% led by Pain Treatments (+6.4%) and Surgical Solutions (+9.3%).","Cash from operations $30.1M, +192% YoY; reaffirms FY2025 revenue $560-570M and Adj. EBITDA $112-116M.","Entered new credit agreement with $300M term loan and $100M revolver, reducing annual interest by ~$2M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":410187000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139987,"accession_number":"0001665988-25-000016","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q2 organic revenue up 6.2%; EPS $0.11 vs loss; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $147.7M (-2.4% reported); organic revenue +6.2%, driven by double-digit growth in Surgical Solutions and Restorative Therapies.","Diluted EPS $0.11 vs loss of $0.40; non-GAAP EPS $0.21, up 31% YoY on lower interest and equity compensation.","Adjusted EBITDA $33.8M vs $34.5M; cash from operations $25.9M, up 71%.","Reaffirmed FY2025 guidance: revenue $560-570M, Adjusted EBITDA $112-116M, non-GAAP EPS $0.64-0.68.","Received FDA 510(k) clearance for TalisMann and StimTrial PNS systems in July 2025, addressing chronic nerve pain."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":271536000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139986,"accession_number":"0001193125-25-172192","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bioventus enters $400M credit facility to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M revolving credit facility and $300M term loan A facility, maturing July 31, 2030.","Initial interest rate: Term SOFR + 2.50% margin, subject to performance grid (1.75%-2.75%).","$30M drawn on revolver at closing; proceeds used to refinance existing 2019 credit facilities.","Financial covenants: max total net leverage ratio 4.00x (step down to 3.50x), min interest coverage 2.50x.","Facility secured by substantially all assets; includes $7.5M L/C and $7.5M swingline subfacilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139985,"accession_number":"0001665988-25-000013","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioventus receives FDA 510(k) clearances for TalisMann and StimTrial PNS products","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted 510(k) clearance for TalisMann PNS system with integrated pulse generator for deeper/larger nerves.","StimTrial is a trial lead to evaluate patient response, expected to aid physician adoption and payer reimbursement.","Limited commercial release in select U.S. markets in Q3 2025; broader rollout planned for early 2026.","PNS market growing >20% annually, expected to exceed $500M by 2029, representing a growth opportunity.","Company offers comprehensive PNS portfolio for chronic pain management with non-opioid, minimally invasive therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157602,"accession_number":"0001665988-25-000010","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bioventus shareholders elect all six director nominees, ratify Grant Thornton as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six Class I director nominees elected with 58M to 64.9M votes; broker non-votes 8.59M each.","Ratification of Grant Thornton as auditor: 73.46M for, 149k against, 11k abstain.","Turnout: 73.62M shares (89.76% of outstanding) present at June 3, 2025 annual meeting.","Directors elected until 2026 annual meeting: Claypoole, Cowdy, McMurry-Heath, Neels, Nohra, Sutter.","No other business voted on; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157601,"accession_number":"0001628280-25-022400","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.","Non-GAAP EPS $0.08, up 33% YoY; Adjusted EBITDA $19.2M vs $22.6M prior due to divestiture.","Pain Treatments +3.9%, Surgical Solutions +7.0%, Restorative Therapies -35.3% (reflecting rehab divestiture).","FY2025 guidance reaffirmed: revenue $560-570M, Adj. EBITDA $112-116M, Non-GAAP EPS $0.64-0.68.","Entered distribution agreement for XCELL PRP system; added new senior leaders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":123876000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175977,"accession_number":"0001628280-25-011830","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).","FY2024 revenue $573.3M (+11.9%); net loss $43.8M vs ($121.2M); adj EBITDA $108.9M (+22.5%).","FY2025 guidance: net sales $560-570M, adj EBITDA $112-116M, non-GAAP EPS $0.64-$0.68.","Debt reduced by $48.3M in Q4; Advanced Rehabilitation Business divested for $24.7M proceeds.","Pain Treatments and Surgical Solutions each delivered double-digit revenue growth for fifth straight quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175976,"accession_number":"0001628280-25-000253","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Bioventus completes divestiture of Advanced Rehab business to Accelmed for $25M cash plus $20M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of Advanced Rehabilitation business to Accelmed Partners on Dec 31, 2024.","Received $25M cash at closing, subject to working capital adjustments.","Up to $20M in earn-out payments based on 2025-2026 revenue and EBITDA thresholds.","Net closing proceeds of approx $20M to enhance liquidity; company to focus on core businesses.","Accelmed is a private equity firm focused on commercial-stage HealthTech companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192894,"accession_number":"0001628280-24-045112","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).","Non-GAAP EPS $0.06 vs $0.05; GAAP loss per share $0.07 vs $0.12.","Pain Treatments +16.7%, Surgical Solutions +18.5%, Restorative Therapies +1.2% (all YoY).","Agreed to divest Advanced Rehabilitation Business for up to $45M; close expected late 2024/early 2025; proceeds to reduce debt.","FY2024 guidance: net sales $562-567M, Adj. EBITDA $104-107M, Non-GAAP EPS $0.40-0.42 (midpoints raised)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":419638000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192893,"accession_number":"0001628280-24-042266","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bioventus divests Advanced Rehabilitation business to Accelmed for up to $45M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration of $45M: $25M at close plus up to $20M in earn-outs.","Net proceeds of ~$20M after fees and expenses will be used to repay existing debt.","Divestiture reduces annual revenue by ~$50M and annual Adj. EBITDA by ~$6M.","Transaction expected to close in Q4 2024, subject to customary conditions.","Bioventus to focus on core business and improve liquidity with the sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209291,"accession_number":"0001628280-24-034976","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.","Net loss from continuing operations $32.1M vs $4.7M, including $31.9M impairment and litigation settlement.","Adjusted EBITDA $34.5M (+22.4% YoY); non-GAAP EPS $0.19 vs $0.14.","Raising FY2024 guidance: revenue $557-567M, adjusted EBITDA $104-107M, non-GAAP EPS $0.36-0.42.","FDA clearance for OSTEOAMP Cannula; pursuing divestiture of Advanced Rehabilitation to reduce debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":280674000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209290,"accession_number":"0001193125-24-181655","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bioventus settles securities class action for $15.25M; insurers to cover ~$6.5M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement amount $15.25M plus interest, subject to court approval; all claims against Bioventus and defendants dismissed.","Insurers expected to pay approximately $6.5M of the settlement; no admission of liability or wrongdoing by any party.","Lawsuit alleged failure to disclose rebate practices, financial prospects, and internal controls; Exchange Act claims survived motion to dismiss.","Settlement reached July 15, 2024; payment due within 30 days after court preliminary approval and receipt of transfer info."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227252,"accession_number":"0001193125-24-165735","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bioventus amends stockholders agreement to phase out classified board structure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Stockholders Agreement moves to annual director elections after 2024 annual meeting.","Existing three-year terms for current directors continue until expiration; successors will serve one-year terms.","Company authorized to amend charter and bylaws to reflect declassification of the Board.","Change applies to director designees of Essex and S+N principal stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227251,"accession_number":"0001193125-24-162669","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Bioventus stockholders approve board declassification, annual director elections by 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Declassification Charter Amendment approved: 61,439,110 for, 135,200 against, 22,572 abstain.","Board will shift to annual elections; entire board elected yearly starting 2026 annual meeting.","Class III directors elected: Robert E. Claypoole, Philip G. Cowdy, Martin P. Sutter.","Ratification of Grant Thornton as auditor for FY 2024: 71,179,096 for, 14,660 against.","Amendment effective upon filing certificate of amendment with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227250,"accession_number":"0001628280-24-020843","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 revenue $129.5M (+8.7% YoY), guides FY24 higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $6.0M vs $100.0M prior year; diluted loss per share $0.07 vs $1.28.","Pain Treatments revenue $56.7M (+23.5% US); Surgical Solutions revenue $42.3M (+19.0% US).","Adjusted EBITDA $22.6M, up 33.5% YoY; adjusted gross margin expanded 190 bps.","FY 2024 guidance raised: net sales $535-550M, Adj. EBITDA $94-99M, Non-GAAP EPS $0.25-0.33.","Organic revenue growth 15.3% driven by Pain Treatments and Surgical Solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":129457000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246139,"accession_number":"0001628280-24-010371","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q4 revenue up 7.6% to $135.4M; guides FY2024 sales $520-535M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $135.4M (+7.6% reported; +14.3% organic); Pain Treatments grew >20%.","Net loss from continuing ops $7.7M vs $35.4M prior year; adjusted EBITDA $22.0M (+28.1%).","Full year 2023 revenue $512.3M (flat YoY); net loss $121.2M vs $144.7M; adj. EBITDA $88.9M (+29.5%).","Appointed Rob Claypoole as President and CEO, effective prior to Q4 close.","FY2024 guidance: net sales $520-535M, adjusted EBITDA $89-94M, non-GAAP EPS $0.12-$0.20."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246138,"accession_number":"0001193125-24-010779","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bioventus amends credit agreement: new leverage ratio 5.65x-4.00x, interest coverage 1.75x-3.00x, $10M liquidity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bioventus LLC entered into Amendment No. 5 to Credit and Guaranty Agreement on Jan 18, 2024 with lenders and Wells Fargo as agent.","Maximum debt leverage ratio: 5.65x for Mar 2024, stepping down to 4.00x from Jun 2025 onward.","Minimum interest coverage ratio: 1.75x from Mar 2024, stepping up to 3.00x from Dec 2025 onward.","New liquidity covenant requires at least $10M average daily balance per month through Oct 2025.","Borrower paid amendment fee of 0.2% of aggregate Term Loan and Revolving Credit exposure to consenting lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246137,"accession_number":"0001193125-24-007640","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bioventus accelerates vesting of former Interim CEO Bihl's equity awards upon CEO transition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board accelerated all outstanding and unvested equity awards of Anthony P. Bihl III effective January 9, 2024.","Equity awards were originally set to vest in April 2024; acceleration was discretionary under award terms.","Bihl served as Interim President and CEO since April 2023; Robert E. Claypoole succeeded him on January 10, 2024.","Acceleration based on Bihl's performance and contributions to the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263596,"accession_number":"0001193125-23-300412","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bioventus appoints Robert Claypoole as President and CEO effective Jan 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Claypoole appointed President and CEO effective Jan 10, 2024, succeeding interim CEO Anthony Bihl.","Compensation: $800k base, 100% bonus target, $750k sign-on cash, 375k RSUs and 850k options.","Claypoole previously EVP at Mölnlycke Health Care, leading $1.2B wound care; also held senior roles at Medtronic and Covidien.","Company reaffirms full year financial guidance previously announced on November 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263595,"accession_number":"0001628280-23-037183","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus reports Q3 net sales $120.8M (-6.1% YoY), raises 2023 adjusted EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops improved to $8.8M from $101.0M in Q3 2022; loss per share $0.12 vs $1.18.","Adjusted EBITDA from continuing ops $21.7M, down 0.9% YoY; non-GAAP EPS $0.05 vs $0.18.","Pain Treatments revenue grew 3.1% YoY to $53.7M; Surgical Solutions up 5.7% in U.S.","Raised full-year 2023 guidance: net sales $498-505M, adjusted EBITDA $84-87M.","Restorative Therapies fell 34.8% due to Wound Business divestiture; underlying organic sales down 0.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":376922000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280804,"accession_number":"0001628280-23-027947","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q2 2023 net sales $137.1M (-2.3% YoY); Adjusted EBITDA $28.2M (+26%); FY2023 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $4.7M ($0.06 EPS loss) vs $7.7M loss in Q2 2022, improved.","Adjusted EBITDA $28.2M, up 26.1% YoY; Non-GAAP EPS $0.14 vs $0.10.","FY2023 guidance: net sales $490-505M, adjusted EBITDA $75-80M, Non-GAAP EPS ($0.24)-($0.20).","Repaid $60.3M of term loan and revolver; net leverage ratio reduced to 4.33 from 5.50.","Closed sale of Wound Business for $31M in net proceeds, used to repay debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":256128000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299440,"accession_number":"0001628280-23-021758","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Bioventus stockholders approve 2023 Retention Equity Award Plan authorizing 600K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2023 Retention Equity Award Plan, reserving 600,000 shares of Class A common stock for RSUs.","Plan aims to retain critical employees; no awards granted yet; Board approved April 17, 2023, stockholders June 7.","All five Class II director nominees elected with strong shareholder support (82-86% 'for' of votes cast).","Grant Thornton LLP ratified as independent auditor for FY 2023 with 99.9% 'for' votes.","Meeting had 88.78% of outstanding shares represented; about 69.5 million shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299439,"accession_number":"0001628280-23-019872","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Bioventus completes sale of Wound Business for $35M cash + up to $45M earn-out; net ~$30M for debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed divestiture of TheraSkin and TheraGenesis to LifeNet Health on May 22, 2023.","Received $35M cash at close, $5M deferred 18 months, up to $45M earn-out through 2026.","Net proceeds of ~$30M after adjustments and fees used to repay existing debt.","Exclusive Sales Agent Agreement gives LifeNet Health rights to SonicOne in US and Canada.","Pro forma Q1 2023 net sales from continuing ops $112.2M; net loss from cont ops $78.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299438,"accession_number":"0001628280-23-018425","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 net loss $100M on $78.6M impairment; Adj. EBITDA $17M beats expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $119.1M (+1.5% YoY); net loss from cont. ops. $100.0M vs $14.4M loss prior year.","Adjusted EBITDA $17.0M vs $7.2M prior year, exceeding expectations; non-GAAP operating income $13.5M vs $1.9M.","Non-cash $78.6M impairment write-down on Wound Business now classified as held for sale.","Signed purchase agreement to divest Wound Business (annual rev ~$40M, Adj. EBITDA ~$5M) on May 10, 2023.","Cash $47.1M, debt $445.6M; FY 2023 Adj. EBITDA guidance at least $68M excluding Wound Business."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":119059000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299437,"accession_number":"0001193125-23-145668","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bioventus sells wound business to LifeNet Health for up to $85M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration up to $85M: $35M at close, $5M deferred, $45M earn-out.","Net proceeds ~$30M after fees and expenses will be used to repay existing debt.","Divestiture reduces annual revenue by ~$40M and annual adjusted EBITDA by ~$5M.","Transaction expected to close ~1 week before end of May 2023.","Sales Agent Agreement grants LifeNet Health exclusive rights to sell SonicOne in US and Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299436,"accession_number":"0001628280-23-017427","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus delays Q1 10-Q filing; prelim revenue ~$119M, Adj. EBITDA ~$17M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filing delayed due to complexity in tax structure and noncontrolling equity interest calculation.","Preliminary Q1 revenue ~$119M; Adjusted EBITDA ~$17M; no impact on revenue or EBITDA from the calculation.","Company expects to file Form 10-Q by May 16, 2023, and remain in compliance with all financial covenants.","Earnings call rescheduled to May 16, 2023 at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299434,"accession_number":"0001193125-23-097964","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K/A","filed_at":"2023-04-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bioventus finalizes employment terms for Interim CEO Anthony Bihl with $751K base salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $751,000 per year; target annual bonus of 100% of base salary.","Equity awards: options for 198,000 shares and RSUs for 76,000 shares, both vesting fully on first anniversary.","Change-in-control severance: 18 months base salary, 150% target bonus, 18 months COBRA, plus full equity acceleration.","Restrictive covenants include perpetual confidentiality, non-disparagement, and 12-month non-compete (18 months after CIC).","Agreement effective April 5, 2023; signed on April 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299435,"accession_number":"0001193125-23-091610","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bioventus CEO Kenneth Reali departs; Anthony Bihl named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Kenneth Reali transitioned from role on April 3, 2023; resigned as director and officer on April 4.","Anthony P. Bihl III appointed interim CEO and Class III director effective April 5, 2023.","Bihl previously served as CEO of Bioventus LLC (2013-2020) and has public board experience.","Separation agreement provides severance: 18 months base salary, 150% of target bonus, COBRA.","Company states Reali's departure is not related to its operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319591,"accession_number":"0001628280-23-010022","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q4 net loss $44.9M; FY22 net loss $213.4M; removes $350M CartiHeal liabilities","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales Q4 $125.8M (-3.5% YoY); Pain Treatments down 25.4% on higher rebate claims.","FY22 net loss $213.4M vs $9.6M income in 2021; includes $189.2M non-cash impairment.","Adjusted EBITDA Q4 $15.2M vs $28.5M; FY22 $66.3M vs $80.8M.","Settlement on Feb 28, 2023 removed $350M of CartiHeal liabilities; credit agreement amended for covenant relief.","Cash $31.8M, debt $418.1M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319590,"accession_number":"0001628280-23-006335","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Bioventus deconsolidates CartiHeal after settlement, records $88.5M loss on disposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Transferred CartiHeal shares to trustee and paid $10M to former securityholders under settlement agreement.","Deconsolidation effective Feb 27, 2023; CartiHeal treated as discontinued operation with $88.5M loss on disposal.","Pro forma net loss for nine months ended Oct 1, 2022 increases to $134.3M from $126.8M historical.","Settlement resolves non-payment of $50M milestone triggered Feb 13, 2023; company avoids litigation.","Bioventus retains no ownership or voting rights in CartiHeal during interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319589,"accession_number":"0001193125-23-052192","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["1.01","7.01"],"status":"ready","headline":"Bioventus settles CartiHeal option for $10M, eliminates up to $350M in contingent payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bioventus LLC paid $10M non-refundable to CartiHeal securityholders and $150k to expense fund.","Mutual release of claims; escrowed CartiHeal shares returned to trustee for securityholders.","Eliminated obligations of $215M in Post-Closing Tranches plus interest, or up to $350M if Sales Milestone triggered.","Bioventus retains option to pay full $215M+ within 30-60 days to reinstate acquisition and Sales Milestone.","CartiHeal to operate in ordinary course during Interim Period with $2M cash minimum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319588,"accession_number":"0001628280-23-000737","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bioventus appoints John A. Bartholdson to board as Class II director effective Jan 8, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John A. Bartholdson, 52, co-founder and Partner at Juniper Investment Company, appointed to Bioventus board effective Jan 8, 2023.","He will serve as Class II director until 2023 annual meeting or successor elected.","Bartholdson receives annual cash retainer of $55,000 and initial RSU award valued at $152,000.","He brings 25 years experience in private/public equity, currently chairs Theragenics board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337792,"accession_number":"0001628280-22-031531","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Bioventus announces restructuring; expects $4-5M pre-tax costs, $9-10M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restructuring announced Dec 6, 2022 to align cost structure and improve profitability and cash flow.","Pre-tax costs of $4-5M: $3-4M employee severance/benefits, $1M third-party costs. All cash costs.","Restructuring expected to be completed by end of 2023.","Expected annualized cost savings of $9-10M upon completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337789,"accession_number":"0001628280-22-030565","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K/A","filed_at":"2022-11-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus amends Q3 results with $189M impairment; cuts FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $145.7M ($1.76 loss per share) vs $2.3M loss in prior year; includes $189.2M non-cash impairment.","Net sales of $128.7M, +18.2% YoY; organic sales down 0.5%.","FY2022 guidance cut: net sales now $517-522M (prev $547.5-562.5M); Adj. EBITDA $75-79M (prev $94-104M).","Non-GAAP EPS guidance lowered to $0.20-0.25 from $0.47-0.57.","Company discontinued development of MOTYS drug candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":386283000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337791,"accession_number":"0001628280-22-030171","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus warns of $185M-$205M impairment, rebate dispute; evaluating going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary review indicates a non-cash impairment charge of $185M to $205M for Q3 2022.","Disputed rebate invoice from a large private payer in Pain Treatments likely to reduce Q3 revenue and may affect revenue guidance.","Management concludes internal controls for quarterly rebate recognition were inadequate for period ended Oct 1, 2022.","Evaluating ability to meet financial obligations within one year; considering mitigation steps.","Expects to file Form 10-Q by Nov 21, 2022, using 12b-25 extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337790,"accession_number":"0001628280-22-028761","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q3 net sales up 25.9% to $137.1M, but cuts full-year 2022 guidance sharply","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $137.1M (+25.9% YoY); net income $3.2M vs net loss $2.3M prior year.","Adjusted EBITDA $22.7M (+$1.3M YoY); Non-GAAP EPS $0.08, down from $0.19 prior year.","Full-year 2022 guidance lowered: net sales $527-532M, Adj. EBITDA $75-79M, Non-GAAP EPS $0.20-0.25.","Debt increased to $424.4M from $357.7M at Dec 2021; cash $34.4M.","CEO highlights recent CartiHeal acquisition to enter large cartilage replacement market."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":386283000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355156,"accession_number":"0001628280-22-025553","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K/A","filed_at":"2022-09-27T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Bioventus files CartiHeal audited financials: 2021 net loss $10.2M, zero revenue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CartiHeal had $0 revenue in 2021; net loss $10.2M; accumulated deficit $67.7M.","R&D expenses $7.8M; cash and equivalents $4.9M at Dec 31, 2021.","Acquisition closed July 12, 2022 for ~$315M upfront plus up to $135M in sales milestones.","Unaudited pro forma combined financials reflect acquisition for six months ended July 2, 2022 and FY 2021.","CartiHeal's Agili-C implant received FDA PMA in March 2022; pre-launch inventory provision of $642K reversed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355159,"accession_number":"0001628280-22-024088","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Stavros Vizirgianakis resigns from Bioventus board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation effective August 29, 2022, not due to any disagreement.","No material change in beneficial ownership expected.","Company has no plans to fill the vacancy at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355158,"accession_number":"0001628280-22-022333","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q2 net sales up 27.8% to $140.3M; net loss improves to $8.0M; updates FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $140.3M (+27.8% YoY); organic growth of 8.1%. Surgical Solutions vertical up 77.2%.","GAAP net loss of ($8.0M) vs ($10.8M) in Q2 2021; diluted loss per share ($0.11) vs ($0.10).","Adjusted EBITDA of $22.9M vs $19.9M YoY; Non-GAAP EPS $0.10 vs $0.11.","FY22 guidance narrowed: net sales $547.5-562.5M (mid-point unchanged); adjusted EBITDA $94-104M.","Discontinued MOTYS development; completed CartiHeal acquisition on July 12, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":257621000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355157,"accession_number":"0001628280-22-018848","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["1.01","2.01","2.03","9.01"],"status":"ready","headline":"Bioventus closes CartiHeal acquisition for $315M upfront; $80M term loan funded","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired CartiHeal for ~$315M upfront plus up to $135M in sales milestone earn-outs.","Acquisition closed July 12, 2022; $100M paid at closing, $215M deferred in tranches through 2027.","Funded part of purchase with $80M term loan (2022-1 Term Loans) maturing Oct 29, 2026.","Term loan bears interest at SOFR + 3.25% or Base Rate + 2.25% with leverage-based margins.","Credit agreement amended; financial covenants include max leverage 4.75x and min interest coverage 2.25x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373261,"accession_number":"0001193125-22-185142","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bioventus CCO John Nosenzo to retire Oct 1; role not replaced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John E. Nosenzo, Chief Commercial Officer, to retire effective October 1, 2022.","Company will not replace CCO role; sales management responsibilities transition to three promoted direct reports.","Transition plan agreed on June 27, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373260,"accession_number":"0001628280-22-017806","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bioventus amends CartiHeal acquisition, defers $215M upfront, lowers sales milestone to $75M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deferred $215M of $315M upfront; paid in five tranches 2023–2027 with 8% annual interest.","Contingent ~$135M now triggered at $75M trailing sales (down from $100M).","Expected close by end of July 2022; upfront ~$100M (incl. $50M escrowed).","Bioventus to pay ~$8M of CartiHeal's transaction fees.","Additional milestones: First Paper $50M, Additional Publication $25M, etc., with interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373259,"accession_number":"0001628280-22-017685","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bioventus shareholders elect four Class I directors, ratify Grant Thornton as auditor for 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class I directors: McMurry-Heath (60,416,389 for), Neels (56,271,187), Nohra (56,281,977), Vizirgianakis (60,862,412); broker non-votes 7,070,353 each.","Ratified Grant Thornton LLP as independent auditor for 2022 with 67,929,557 for, 89,283 against, 6,345 abstained (no broker non-votes).","Annual Meeting had 68,025,185 shares present (88.5% of outstanding common stock)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373258,"accession_number":"0001628280-22-013461","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 net loss $14.8M vs prior-year income; reaffirms FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $117.3M (+43.4% YoY as reported, +8.6% organic); Pain Treatments +25.3%, Restorative Therapies +57.5%, Surgical Solutions +67.6%.","Net loss of ($14.8M) compared to net income of $24.5M in Q1 2021; Adjusted EBITDA $7.1M vs $11.1M.","Reaffirms FY2022 guidance: net sales $545M-$565M, Adjusted EBITDA $94M-$107M.","Cash $27.4M; debt $368.3M as of April 2, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":117290000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-10T23:59:59+00:00|373258"}